New Data Available on KEVEYIS for PPP
https://unsplash.com/photos/8ztH-7lj8ag

New Data Available on KEVEYIS for PPP

In a news release from mid-July, 2021, biopharmaceutical company Strongbridge Biopharma plc ("Strongbridge") shared the publication of new post hoc analyses regarding KEVEYIS (dichlorphenamide) for patients with Primary Periodic Paralysis…

Continue Reading New Data Available on KEVEYIS for PPP
EHA2021: Longer-Term Data Presented on Yescarta for R/R Follicular Lymphoma
https://pixabay.com/photos/hospital-infusion-hand-association-834157/

EHA2021: Longer-Term Data Presented on Yescarta for R/R Follicular Lymphoma

During the European Hematology Association (EHA)'s 26th Annual Meeting, taking place virtually, biopharmaceutical company Kite (part of Gilead) shared longer-term follow-up data on Yescarta (axicabtagene ciloleucel) for patients with relapsed…

Continue Reading EHA2021: Longer-Term Data Presented on Yescarta for R/R Follicular Lymphoma